• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Arena Pharmaceuticals, Inc.

    Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Reports Third Quarter Financial Results and Key Program Updates
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Reports Second Quarter Financial Results and Key Program Updates
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Arena Pharmaceuticals, Inc.
    Via Business Wire
    Tickers ARNA
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.